Therapeutic enhancement of vascular-targeted photodynamic therapy by inhibiting proteasomal function

Cancer Letters

Volumn 339, Issue 1, 2013, Pages 128-134

  Li, Zhuzhu ^a   Agharkar, Priyanka ^a   Chen, Bin ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Apoptosis; Bortezomib; Combination therapy; Reactive oxygen species (ROS); Ubiquitination; Vascular targeted photodynamic therapy (vPDT); Verteporfin

Indexed keywords

BORTEZOMIB; CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; VERTEPORFIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DRUG EFFICACY; DRUG RESPONSE; ENDOTHELIUM CELL; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; TREATMENT RESPONSE; TUMOR GROWTH; UBIQUITINATION;

APOPTOSIS; BORTEZOMIB; COMBINATION THERAPY; REACTIVE OXYGEN SPECIES (ROS); UBIQUITINATION; VASCULAR-TARGETED PHOTODYNAMIC THERAPY (VPDT); VERTEPORFIN;

ANIMALS; APOPTOSIS; BLOOD VESSELS; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; ENDOTHELIAL CELLS; HUMANS; MALE; MICE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; REACTIVE OXYGEN SPECIES; TRANSPLANTATION, HETEROLOGOUS; UBIQUITINATION;

EID: 84883466062     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.012     Document Type: Article

References (39)

1. Agostinis P., Berg K., Cengel K.A., Foster T.H., Girotti A.W., Gollnick S.O., Hahn S.M., Hamblin M.R., Juzeniene A., Kessel D., Korbelik M., Moan J., Mroz P., Nowis D., Piette J., Wilson B.C., Golab J. Photodynamic therapy of cancer: an update. CA Cancer J. Clin. 2011, 61:250-281.
2. Brown S.B., Brown E.A., Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet. Oncol. 2004, 5:497-508.
3. Krammer B. Vascular effects of photodynamic therapy. Anticancer Res. 2001, 21:4271-4277.
4. Chen B., Pogue B.W., Hoopes P.J., Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit. Rev. Eukaryotic Gene Exp. 2006, 16:279-305.
5. Chen B., Pogue B.W., Hoopes P.J., Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61:1216-1226.
6. Chen B., Pogue B.W., Luna J.M., Hardman R.L., Hoopes P.J., Hasan T. Tumor vascular permeabilization by vascular-targeting photosensitization: effects, mechanism, and therapeutic implications. Clin. Cancer Res. 2006, 12:917-923.
7. Richter A.M., Waterfield E., Jain A.K., Allison B., Sternberg E.D., Dolphin D., Levy J.G. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. Br. J. Cancer 1991, 63:87-93.
8. He C., Agharkar P., Chen B. Intravital microscopic analysis of vascular perfusion and macromolecule extravasation after photodynamic vascular targeting therapy. Pharm. Res. 2008, 25:1873-1880.
9. Gross S., Gilead A., Scherz A., Neeman M., Salomon Y. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat. Med. 2003, 9:1327-1331.
10. Madar-Balakirski N., Tempel-Brami C., Kalchenko V., Brenner O., Varon D., Scherz A., Salomon Y. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad. PloS one 2010, 5:e10282.
11. Byrne A.T., O'Connor A.E., Hall M., Murtagh J., O'Neill K., Curran K.M., Mongrain K., Rousseau J.A., Lecomte R., McGee S., Callanan J.J., O'Shea D.F., Gallagher W.M. Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment. Br. J. Cancer 2009, 101:1565-1573.
12. Granville D.J., Shaw J.R., Leong S., Carthy C.M., Margaron P., Hunt D.W., McManus B.M. Release of cytochrome c, Bax migration, Bid cleavage, and activation of caspases 2, 3, 6, 7, 8, and 9 during endothelial cell apoptosis. Am. J. Pathol. 1999, 155:1021-1025.
13. Petermeier K., Tatar O., Inhoffen W., Volker M., Lafaut B.A., Henke-Fahle S., Gelisken F., Ziemssen F., Bopp S., Bartz-Schmidt K.U., Grisanti S. Verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes. Br. J. Ophthalmol. 2006, 90:1034-1039.
14. Khurana M., Moriyama E.H., Mariampillai A., Wilson B.C. Intravital high-resolution optical imaging of individual vessel response to photodynamic treatment. J. Biomed. Opt. 2008, 13:040502.
15. Szokalska A., Makowski M., Nowis D., Wilczynski G.M., Kujawa M., Wojcik C., Mlynarczuk-Bialy I., Salwa P., Bil J., Janowska S., Agostinis P., Verfaillie T., Bugajski M., Gietka J., Issat T., Glodkowska E., Mrowka P., Stoklosa T., Hamblin M.R., Mroz P., Jakobisiak M., Golab J. Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response. Cancer Res. 2009, 69:4235-4243.
16. Magi B., Ettorre A., Liberatori S., Bini L., Andreassi M., Frosali S., Neri P., Pallini V., Di Stefano A. Selectivity of protein carbonylation in the apoptotic response to oxidative stress associated with photodynamic therapy: a cell biochemical and proteomic investigation. Cell Death Differ. 2004, 11:842-852.
17. Xue L.Y., Agarwal M.L., Varnes M.E. Elevation of GRP-78 and loss of HSP-70 following photodynamic treatment of V79 cells: sensitization by nigericin. Photochem. Photobiol. 1995, 62:135-143.
18. Luna M.C., Ferrario A., Wong S., Fisher A.M., Gomer C.J. Photodynamic therapy-mediated oxidative stress as a molecular switch for the temporal expression of genes ligated to the human heat shock promoter. Cancer Res. 2000, 60:1637-1644.
19. Ferrario A., Gomer C.J. Targeting the 90 kDa heat shock protein improves photodynamic therapy. Cancer Lett. 2010, 289:188-194.
20. Korbelik M., Sun J., Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res. 2005, 65:1018-1026.
21. Mitra S., Giesselman B.R., De Jesus-Andino F.J., Foster T.H. Tumor response to mTHPC-mediated photodynamic therapy exhibits strong correlation with extracellular release of HSP70. Lasers Surgery Med. 2011, 43:632-643.
22. Curry P.M., Levy J.G. Stress protein expression in murine tumor cells following photodynamic therapy with benzoporphyrin derivative. Photochem. Photobiol. 1993, 58:374-379.
23. O'Connor A.E., Mc Gee M.M., Likar Y., Ponomarev V., Callanan J.J., O'Shea D F., Byrne A.T., Gallagher W.M. Mechanism of cell death mediated by a BF2-chelated tetraaryl-azadipyrromethene photodynamic therapeutic: dissection of the apoptotic pathway in vitro and in vivo. Int. J. Cancer 2012, 130:705-715.
24. Moserova I., Kralova J. Role of ER stress response in photodynamic therapy: ROS generated in different subcellular compartments trigger diverse cell death pathways. PloS One 2012, 7:e32972.
25. Tobinai K. Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int. J. Clin. Oncol. 2007, 12:318-326.
26. Brown S.B., Mellish K.J. Verteporfin: a milestone in opthalmology and photodynamic therapy. Exp. Opin. Pharmacother 2001, 2:351-361.
27. Fateye B., Li W., Wang C., Chen B. Combination of phosphatidylinositol 3-kinases pathway inhibitor and photodynamic therapy in endothelial and tumor cells. Photochem. Photobiol. 2012, 88:1265-1272.
28. Chen B., Roskams T., Xu Y., Agostinis P., de Witte P.A. Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Int. J. Cancer 2002, 98:284-290.
29. Moore C.M., Emberton M., Bown S.G. Photodynamic therapy for prostate cancer - an emerging approach for organ-confined disease. Lasers Surgery Med. 2011, 43:768-775.
30. Chen B., Pogue B.W., Zhou X., O'Hara J.A., Solban N., Demidenko E., Hoopes P.J., Hasan T. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin. Cancer Res. 2005, 11:720-727.
31. Granville D.J., Levy J.G., Hunt D.W. Photodynamic therapy induces caspase-3 activation in HL-60 cells. Cell Death Differ. 1997, 4:623-628.
32. Peng T.I., Chang C.J., Guo M.J., Wang Y.H., Yu J.S., Wu H.Y., Jou M.J. Mitochondrion-targeted photosensitizer enhances the photodynamic effect-induced mitochondrial dysfunction and apoptosis. Ann. NY Acad. Sci. 2005, 1042:419-428.
33. Runnels J.M., Chen N., Ortel B., Kato D., Hasan T. BPD-MA-mediated photosensitization in vitro and in vivo: cellular adhesion and beta1 integrin expression in ovarian cancer cells. Br. J. Cancer 1999, 80:946-953.
34. Belzacq A.S., Jacotot E., Vieira H.L., Mistro D., Granville D.J., Xie Z., Reed J.C., Kroemer G., Brenner C. Apoptosis induction by the photosensitizer verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target. Cancer Res. 2001, 61:1260-1264.
35. Komander D., Rape M. The ubiquitin code. Ann. Rev. Biochem. 2012, 81:203-229.
36. Johnson G.G., White M.C., Grimaldi M. Stressed to death: targeting endoplasmic reticulum stress response induced apoptosis in gliomas. Curr. Pharm. Des. 2011, 17:284-292.
37. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
38. Granville D.J., Carthy C.M., Jiang H., Levy J.G., McManus B.M., Matroule J.Y., Piette J., Hunt D.W. Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin. Blood 2000, 95:256-262.
39. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.